Clinical trials: Hidradenitis Suppurativa
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
- Trial name
- NCT02805595
- Testing
- 23.4% Hypertonic saline
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
- Trial name
- NCT04493502
- Testing
- LY3041658
- Where
- 20 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Hidradenitis Suppurativa
Hidradenitis Suppurativa Phase 2b Study of Izokibep
Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being developed for treatment of hidradenitis suppurativa (HS).
- Trial name
- NCT05355805
- Testing
- Izokibep
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 205 people
- Sponsor
- ACELYRIN Inc.
Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa Wound Care
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape.
- Trial name
- NCT04354012
- Testing
- methylene blue, gentian violet, and ovine forestomach wound dressings
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Hidradenitis Suppurativa
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT02904902
- Testing
- adalimumab
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
- Trial name
- SHARPS (NCT02808975)
- Testing
- Adalimumab
- Where
- 55 sites in United States, Belgium and 21 more
- Volunteers
- 206 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study.
- Trial name
- NCT05997277
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
- Trial name
- NCT05348681
- Testing
- RIST4721
- Where
- 12 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Aristea Therapeutics, Inc.
Hidradenitis Suppurativa
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
- Trial name
- NCT03248531
- Testing
- Bimekizumab, Adalimumab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- NCT05216224
- Testing
- ATI-450
- Where
- 20 sites in United States
- Volunteers
- 95 people
- Sponsor
- Aclaris Therapeutics, Inc.
Hidradenitis Suppurativa
A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial
This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study.
- Trial name
- NCT04876391
- Testing
- Spesolimab 1200 mg, Spesolimab 600 mg
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT03569371
- Testing
- INCB054707
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS
The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and effective for treating hidradenitis suppurativa.
- Trial name
- NCT00722800
- Testing
- drospirenone and ethinyl estradiol (YAZ)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa, Hidradenitis
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body.
- Conditions
- Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils
- Trial name
- NCT03275870
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Elena Gonzalez Brant, MD
Hidradenitis Suppurativa
Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab.
- Trial name
- HOPE (NCT02739828)
- Testing
- Adalimumab
- Where
- 11 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week…
- Trial name
- STOP-HS2 (NCT05620836)
- Testing
- Povorcitinib
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 619 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD I (NCT04242446)
- Testing
- Bimekizumab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 505 people
- Sponsor
- UCB Biopharma SRL